Cowen & Co. analyst Boris Peaker maintained a Hold rating on Seattle Genetics (SGEN) yesterday and set a price target of $80. The company’s shares closed yesterday at $67.86.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 2.5% and a 40.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Seattle Genetics is a Moderate Buy with an average price target of $76.71.
See today’s analyst top recommended stocks >>
The company has a one-year high of $84.37 and a one-year low of $50.71. Currently, Seattle Genetics has an average volume of 830.6K.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SGEN in relation to earlier this year. Most recently, in March 2019, Clay Siegall, the President & CEO of SGEN bought 16,556 shares for a total of $199,988.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
